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Simple Summary: Thymic epithelial tumors and lymphomas are the most frequent mediastinal mass
lesions. Thymic hyperplasia with “lymphoepithelial sialadenitis (LESA)-like features” (LESA-like
TH) was initially described as one form of thymic hyperplasia and was thought not to be associated
with autoimmune and lymphoproliferative diseases. Our systematic analysis of patients with LESA-
like TH shows that 14% have associated lymphomas and 33% partially overlapping autoimmune
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diseases. This implies a hematologic and rheumatologic workup in patients with LESA-like TH.
In addition, LESA-like TH should enter the list of differential diagnoses of mediastinal mass lesions,
in particular in patients with autoimmune diseases.
Abstract: Thymic hyperplasia (TH) with lymphoepithelial sialadenitis (LESA)-like features (LESA-
like TH) has been described as a tumor-like, benign proliferation of thymic epithelial cells and
lymphoid follicles. We aimed to determine the frequency of lymphoma and autoimmunity in LESA-
like TH and performed retrospective analysis of cases with LESA-like TH and/or thymic MALT-
lymphoma. Among 36 patients (21 males) with LESA-like TH (age 52 years, 32–80; lesion diameter 7.0
cm, 1–14.5; median, range), five (14%) showed associated lymphomas, including four (11%) thymic
MALT lymphomas and one (3%) diffuse large B-cell lymphoma. One additional case showed a clonal
B-cell-receptor rearrangement without evidence of lymphoma. Twelve (33%) patients (7 women)
suffered from partially overlapping autoimmune diseases: systemic lupus erythematosus (n = 4,
11%), rheumatoid arthritis (n = 3, 8%), myasthenia gravis (n = 2, 6%), asthma (n = 2, 6%), scleroderma,
Sjögren syndrome, pure red cell aplasia, Grave’s disease and anti-IgLON5 syndrome (each n = 1, 3%).
Among 11 primary thymic MALT lymphomas, remnants of LESA-like TH were found in two cases
(18%). In summary, LESA-like TH shows a striking association with autoimmunity and predisposes
to lymphomas. Thus, a hematologic and rheumatologic workup should become standard in patients
diagnosed with LESA-like TH. Radiologists and clinicians should be aware of LESA-like TH as a
differential diagnosis for mediastinal mass lesions in patients with autoimmune diseases.
Keywords: autoimmune disease; imaging; LESA; lymphoma; myasthenia; pathology; surgery;
thymus; thymic epithelial tumor; thymitis
1. Introduction
Thymic epithelial tumors (thymomas and thymic carcinomas) and lymphomas repre-
sent the two most frequent types of mediastinal neoplasms in adults [1]. Non-neoplastic
mediastinal masses mainly consist of cysts and several types of thymic hyperplasia:
(i) true thymic hyperplasia of unknown etiology that shows normal-looking histology
and a thymus weight that mostly exceeds 100 g, (ii) rebound hyperplasia that follows the
cessation of various “stressors” such as infection or chemotherapy and shows normal-for-
age or juvenile histology and organ weights usually below 100 g, (iii) diseases with the
unifying histological hallmark of lymphofollicular hyperplasia. In this group, the paradig-
matic and most frequent disease is the “conventional thymitis” with lymphofollicular
hyperplasia that typically occurs in early-onset myasthenia gravis (EOMG) and rarely other
settings and is labelled here as “thymic follicular hyperplasia” (henceforth abbreviated
as TFH). Recently, another condition characterized by lymphofollicular hyperplasia was
described and named “thymic hyperplasia with lymphoepithelial sialadenitis (LESA)-like
features” (henceforth called LESA-like TH) that forms mediastinal mass lesions with diam-
eters between 4 and 22 cm in corticosteroid-naïve patients without MG [2,3]. Those masses
were either detected fortuitously or due to complications following compression of the
heart, great vessels and lung. The reported histological hallmarks included proliferation
of epithelial cells and Hassall corpuscles, cystic changes, lymphoepithelial lesions and
lymphofollicular hyperplasia leading to a replacement of the thymic parenchyma by nu-
merous follicles and plasma cells with consecutive lymph node-like appearance. The five
patients described so far did not show any autoimmune, immune mediated inflammatory
or lymphoproliferative diseases, although such an association might have been anticipated
in analogy to the “true” LESA of salivary glands [4]. Furthermore, the first descriptions
of primary thymic mucosa-associated lymphoid tissue (MALT) lymphomas already high-
lighted the striking similarity with “myoepithelial sialadenitis” [5]. However, until now,
systematic investigations into a relationship between LESA-like TH and lymphomas as
well as autoimmune diseases have not been undertaken.
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The aim of this study, therefore, was to analyze a large cohort of patients with LESA-
like TH in terms of association with autoimmune disorders, lymphomas and histology.
In addition, we screened cases primarily diagnosed as thymic MALT lymphomas for
possible remnants of LESA-like lesions.
2. Materials and Methods
A retrospective analysis of reference pathology cases with LESA-like TH and thymic
lymphomas was performed. The study was approved by the local ethics committee (Medical
Ethics Committee II, Medical Faculty Mannheim of the Heidelberg University, approval
no. 2017-806R-MA). For the sake of simplicity we counted asthma among the autoimmune
diseases, although it is now considered an immune mediated inflammation. The tissue had
been subjected to routine protocols of diagnostic pathology. Rearrangements of the B-cell
receptor were tested by Biomed-2/EuroClonality multiplex PCR primers. Due to the lim-
ited sample quality, it was impossible to perform IGH-FR1 next generation sequencing [6]
to characterize the lymphoma-associated rearrangements more closely. Immunohistochem-
istry was performed using diaminobenzidine (DAB) substrate chromogen detection system
(Dako, Hamburg, Germany) and primary antibodies against IgA, IgD, IgG, IgM (poly-
clonal, Agilent, Frankfurt, Germany A0262, A0093, A0423, A0425), BCL2 (clone: 124), BCL6
(PGB6p), CD5 (4C7), CD10 (56C6), CD20 (L26), CD23 (SP23), CD30 (BerH2), MUM1/IRF4
(MUM1p), cytokeratin 19 (RCK108), desmin (polyclonal, Thermo Scientific, RB-9014P),
kappa/lambda (polyclonal A0191, A0193 Agilent) and TdT (SEN28).
3. Results
3.1. Clinical Presentation
The clinicopathological features of 36 cases of LESA-like TH submitted for reference
pathology from 2011 to 2019 are given in Table 1. The male-to-female ratio was 1.4:1,
and the mean age was 53 ± 12 (SD) years (range 32–80). In all but two cases (94%) the mass
lesions were incidental findings in CT or MRI scans or during surgery for other reasons
(e.g., bypass) (Figure 1). The two symptomatic patients were a 67-year-old man and a
32-year-old woman suffering from MG that was suspected to be thymoma-associated.
Table 1. Clinical data of cases primarily diagnosed with LESA-like TH.
Case Age (y) Sex Size (cm) Autoimmune Disorder Lymphoma
1 57 f 7.0
2 70 m 7.0 clonal JH rearrangementbut no lymphoma
3 47 m 5.0
4 62 f n.r. thymic MALTlymphoma (IgG)
5 50 m 3.5
6 45 m 6.5
7 65 f 8.5
8 38 m n.r. Grave’s disease
9 57 m n.r.
10 55 m n.r.
11 51 m n.r.
12 47 m 8.5
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Table 1. Cont.
Case Age (y) Sex Size (cm) Autoimmune Disorder Lymphoma
13 54 f 1.0 pure red cell aplasia
14 44 f n.r.
15 45 m n.r.
16 80 m 3.5
17 51 f 9.0 rheumatoid arthritis,asthma
18 52 m n.r.
19 43 f 8.0
20 54 f n.r.
21 62 m 4.0 rheumatoid arthritis




not typical for MG but
MuSK-positive
23 42 m 5.4
24 60 f 4.5 asthma
25 39 f 5.6 thymic MALTlymphoma (IgG)
26 35 f 9.0
27 67 f n.r. SLE
28 61 m 14.5
29 70 m 10.0 Sjögren syndrome, SLE,rheumatoid arthritis
thymic MALT
lymphoma (IgM)
30 32 f 7.0 MG (AChR-positive;MuSK, titin-negative)
31 35 m n.r. thymic MALTlymphoma (IgG)
32 67 m 7.0 MG (titin-positive,AChR low)
33 47 f 12.0 SLE, scleroderma
34 65 m 6.0 diffuse large B-celllymphoma (n.hcr.)
35 66 m n.r. anti-IgLON5-Syndrom
36 39 m 17
AChR, acetylcholine receptor; MALT, mucosa-associated lymphatic tissue; MG, myasthenia gravis; n.hcr., no heavy
chain restriction detectable in immunohistochemistry; n.r., not reported; SLE, systemic lupus erythematosus.
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Figure 1. Magnetic resonance imaging in a LESA-like TH patient: Mediastinal mass-forming lesion 
with a diameter of 35 mm (arrows) in a patient with LESA-like TH (incidental finding). 
3.2. Histological Findings 
Histology consistently revealed a tumor-forming process with a lymph node-like 
appearance (Figure 2A–C). Cysts lined by squamous epithelium with occasional choles-
terol crystals were frequent. The lesions often did not involve the whole thymus but 
spared thymic lobes that showed mild to moderate “conventional” lymphofollicular 
hyperplasia. The medullary epithelium was hyperplastic and readily discernible as tra-
beculae and networks in immunostains for CK19, while in conventional HE stains its 
hyperplastic character was sometimes obscured by prominent lymphoid infiltrates that 
elicited lymphoepithelial lesions (Figure 2D,E). Hassall corpuscles were consistently 
maintained and often hyperplastic with a microcystic change. The lymphocytic infiltrate 
consisted of mature B-cells and T-cells with numerous germinal centers visualized by 
CD23(+) follicular dendritic cells (Figure 2F,G). In 31 cases (86%), hyperplastic germinal 
centers showed a typical population of CD20(+), Bcl2(−), Bcl6(+) and CD10(+) B-cells 
(Figure 2H–J). In contrast to unaffected lobes, those with full-blown LESA-like TH 
showed cortical atrophy with complete or subtotal absence of immature, TdT(+) T-cells 
(Figure 2K). The number of desmin(+) myoid cells was unremarkable. 
Figure 1. Magnetic resonance imaging in a LESA-like TH patient: Mediastinal mass-forming lesion with a diameter of
35 mm (arrows) in a patient with LESA-like TH (incidental finding).
3.2. Histological Findings
Histology consistently revealed a tumor-forming process with a lymph node-like
appearance (Figure 2A–C). Cysts lined by squamous epithelium with occasional cholesterol
crystals were frequent. The lesions often did not involve the whole thymus but spared
thymic lobes that showed mild to moderate “conventional” lymphofollicular hyperplasia.
The medullary epithelium was hyperplastic and readily discernible as trabeculae and net-
works in immunostains for CK19, while in conventional HE stains its hyperplastic character
was sometimes obscured by prominent lymphoid infiltrates that elicited lymphoepithelial
lesions (Figure 2D,E). Hassall corpuscles were consistently maintained and often hyper-
plastic with a microcystic change. The lymphocytic infiltrate onsisted of mature B-cells
nd T-cells with numerous germi al c nter visual zed by CD23(+) fo licular dendritic cells
(Figure 2F,G). In 31 cases (86%), hyperplastic germinal cent s showed a typical population
of CD20(+), Bcl2(−), Bcl6(+) and CD10(+) B-cells (Figure 2H–J). In contrast to unaffected
lobes, those with full-blown LESA-like TH s owed c rtical atrophy with complete or
subtotal absence of immature, TdT(+) T-cells (Figure 2K). The number of desmin(+) myoid
cells was unremarkable.
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Figure 2. Histological findings in LESA-like TH. (A): Low-power magnification revealing lymph node-like change with 
typical cystic structures and remnants of thymus discernible in the upper right corner. (B): Epithelial hyperplasia with 
lymphocytic epitheliotropism and hyperplasia of Hassall corpuscles showing cystic dilatation (inlay). (C–K): Serial sec-
tions capturing the abrupt transition of moderate conventional thymitis (upper part) into the tumor-forming LESA-like 
TH (lower part) in conventional HE morphology (C) and immunohistochemistry for cytokeratin 19 visualizing the hy-
perplastic epithelium with intraepithelial lymphocytes (D,E). Dense B lymphocytic infiltration shown by CD20 (F) with 
prominent CD23-positive follicular dendritic cells (G) colonized by Bcl2-negative (H) and CD10/Bcl6-positive (I,J) lym-
phocytes. As contrasted with the moderate thymitis in the upper part, LESA-like TH is typically devoid of immature 
TdT-expressing T-lymphocytes (K). Micrographs taken from the LESA-like TH case no. 5. Original magnifications: (A): 
1.5×; (B): 20×, inlay 30×; (C,D,F–K): 3×; (E): 15×. 
Figure 2. Histological findings in LESA-like TH. (A): Low-power magnification revealing lymph node-like change with
typical cystic structures and remnants of thymus discernible in the up er right corner. (B): Epithelial hyperplasia with
lymphocytic epitheliotropism and hyperplasia of Hassall corpuscles showing cystic dilatation (inlay). (C–K): Serial sections
capturing the abrupt transition of moderate conventional thymitis (upper part) into the tumor-forming LESA-like TH
(lower part) in conventional HE morphology (C) and immunohistochemistry for cytokeratin 19 visualizing the hyperplastic
epithelium with intraepithelial lymphocytes (D,E). Dense B lymphocytic infiltration shown by CD20 (F) with prominent
CD23-positive follicular dendritic cells (G) colonized by Bcl2-negative (H) and CD10/Bcl6-positive (I,J) lymphocytes.
As contrasted with the moderate thymitis in the upper part, LESA-like TH is typically devoid of immature TdT-expressing
T-lymphocytes (K). Micrographs taken from the LESA-like TH case no. 5. Original magnifications: (A): 1.5×; (B): 20×,
inlay 30×; (C,D,F–K): 3×; (E): 15×.
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Taking the number of mediastinal mass lesions referred for consultation to the Institute
of Pathology, University Medical Centre Mannheim, Germany, into account, one might
roughly estimate the frequency of LESA-like TH as approximately 2% (Table S1). However,
due to the referral bias, the true incidence might rather be lower.
A concomitant thymoma was observed in only one patient. This micronodular thy-
moma with lymphoid stroma was widely separated from the LESA-like TH and showed
features distinctly different from those of LESA-like TH: sharply delineated nodules of
plump spindle epithelial cells, lack of Hassall corpuscles and a lymphoid stroma harboring
immature, TdT(+) T-cells around the epithelial nodules in addition to mature B-cells and
T-cells (Figure S1).
3.3. LESA-Like TH-Associated Lymphomas
In five of 36 patients primarily diagnosed with LESA-like TH (14%), an accompanying
B-cell lymphoma was observed, including four MALT-lymphomas (11%) and one diffuse
large cell B-cell lymphoma (DLBCL, 3%) (Table 1). An additional patient showed a mono-
clonal rearrangement of B-cell receptor genes but no morphological features of lymphoma.
All five lymphomas developed inside or in continuity with the LESA-like TH (Figure 3 and
Figure S2). Among the four MALT-lymphomas, three were restricted for IgG and one for
IgM. The MALT-lymphomas showed enlarged meshworks of CD23(+) follicular dendritic
cells colonized by CD20(+) Bcl2(+), Bcl6(−) and CD10(−) B lymphocytes (Figure 3A–H).
In the case with simultaneous LESA-like TH, MALT lymphoma and autoimmunity (no. 29),
a plasma cell-rich vasculitis was present (Figure 3I). The one LESA-like TH-associated
DLBCL exhibited a germinal center phenotype with expression of CD20, BCL2, BCL6 and
CD10, while typical markers of primary mediastinal large B-cell lymphoma (CD23, CD30,
IRF4/MUM1) were missing.
Among 11 archival cases of primary thymic MALT lymphomas with a male-to-female
ratio of 2:9 and a mean age of 61 ± 14 years (range 34–79), two cases (18%, one male and one
female) showed remnants of LESA-like TH in a retrospective screen. Except for one female
with Sjögren syndrome, these patients did not show autoimmune diseases. A heavy chain
restriction could be documented by immunohistochemistry in five (two IgA, two IgG and
one IgM) out of nine cases with material available for additional investigations (Table 2).
Table 2. Clinical data of cases primarily diagnosed with thymic lymphoma.
Case Age (y) Sex Size (cm) AutoimmuneDisorders
LESA-like
TH Lymphoma
1 34 f n.r. MALT lymphoma (IgG)
2 62 m >10 MALT lymphoma (n.m.)
3 44 f 4.0 present MALT lymphoma (IgA)




5 61 f n.r. MALT lymphoma (n.m.)
6 49 f n.r. MALT lymphoma (n.m.)
7 75 m n.r. present MALT lymphoma (n.hcr.)
8 52 f 4.5 MALT lymphoma (IgG)
9 79 f biopsy MALT lymphoma (n.hcr.)
10 78 f 1.2 MALT lymphoma (n.hcr.)
11 63 f biopsy Sjögrensyndrome MALT lymphoma (IgA)
n.m., no material for additional testing; n.hcr., no heavy chain restriction detectable in immunohistochemistry;
n.r., not reported.
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Figure 3. Marginal zone lymphomas associated with LESA-like TH. (A–F): Serial sections of a LESA-like TH (left) pro-
gressing into a marginal-zone lymphoma (right). The process is readily discernible as a rarefication of the cytokeratin 
19-positive epithelium (B) and expansion of the CD20-positive lymphocytic component (C) with tiny marginal remnants 
of TdT-expressing cortical thymocytes (inlay). The transformation is characterized by atypical and hyperplastic mesh-
works of CD23-positive follicular dendritic cells (D) populated by Bcl2-positive (E) and CD10-negative lymphocytes (F) 
with an abnormally distributed and low Ki67-proliferation in the germinal centers (inlay). (G–H): Prominent secretory 
differentiation and light-chain restriction for kappa (G) in contrast to lambda (H) observed in one of the marginal zone 
lymphomas associated with LESA-like TH. I: Vasculitis in the direct neighborhood of the thymus in the unique patient 
with simultaneous LESA-like TH, MALT lymphoma and autoimmunity (Sjögren syndrome, systemic lupus erythema-
tosus, rheumatoid arthritis). Micrographs taken from the LESA-like TH cases no. 31 (A–F) and 29 (G–I). Original magni-
fications: (A–F): 1.5×, (G,H): 8×; (I): 10×.  
Figure 3. Marginal zone lymphomas associated with LESA-like TH. (A–F): Serial sections of a LESA-like TH (left) pro-
gressing into a marginal-zone lymphoma (right). The process is readily discernible as a rarefication of the cytokeratin
19-positive epithelium (B) and expansion of the CD20-positive lymphocytic component (C) with tiny marginal remnants
of TdT-expressing cortical thymocytes (inlay). The transformation is characterized by atypical and hyperplastic mesh-
works of CD23-positive follicular dendritic cells (D) populated by Bcl2-positive (E) and CD10-negative lymphocytes (F)
with an abnormally distributed and low Ki67-proliferation i the germinal centers (inlay). (G–H): Pro inent secretory
differentiation and light-chain restriction for kappa (G) in contrast to lambda (H) observed in one of the marginal zone
lymphomas associated with LESA-like TH. (I): Vasculitis in the direct neighborhood of the thymus in the unique patient
with simultaneous LESA-like TH, MALT lymphoma and autoimmunity (Sjögren syndrome, systemic lupus erythematosus,
rheumatoid arthritis). Micrographs taken from the LESA-like TH cases no. 31 (A–F) and 29 (G–I). Original magnifications:
(A–F): 1.5×, (G,H): 8×; (I): 10×.
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3.4. LESA-Like TH-Associated Autoimmune Disorders
Twelve patients (33%; five men and seven women) suffered from partially overlapping
autoimmune diseases that were present already at the time of thymectomy: systemic lupus
erythematosus (n = 4, 11%), rheumatoid arthritis (n = 3, 9%), myasthenia gravis (n = 2, 6%),
asthma (n = 2, 6%), Sjögren syndrome, scleroderma, pure red cell aplasia, Grave’s disease
and anti-IgLON5 syndrome (each n = 1, 3%) (Table 1). Of note, among the two patients
with MG, one 68-year-old male patient who was suspected to have a thymoma prior to
surgery showed high anti-titin and low anti-acetylcholine receptor (AChR) autoantibody
titers, i.e., a spectrum of findings that is characteristic of “late-onset MG” (LOMG) in
non-thymoma patients. The other MG patient, a 32-year-old female, showed anti-AChR
antibodies. A third patient presented with non-myasthenic neurological deficits and
showed anti-muscle-specific kinase (MuSK) antibodies.
Unexpectedly, the subgroups of patients with lymphomas and autoimmune diseases
overlapped only in two cases: a 70-year-old male suffering from Sjögren syndrome, systemic
lupus erythematosus, rheumatoid arthritis and thymic MALT lymphoma in the setting of
a LESA-like TH and a 63-year-old female suffering from Sjögren syndrome and thymic
MALT lymphoma without LESA-like TH (Tables 1 and 2 and Figure 4).




Figure 4. Venn diagram visualizing the overlaps between LESA-like TH, lymphomas and auto-
immune diseases. A synopsis of both cohorts, i.e., LESA-like TH (Table 1) and lymphoma (Table 2), 
is shown with the overlaps between the diagnoses of LESA-like TH (LESA), lymphoma (Lym.) and 
autoimmune disorders (Autoimm.) together with the gender distribution (M, male; F, female). Six 
female and 14 male patients showed LESA-like TH only, while one male and seven female patients 
exclusively showed lymphoma. LESA-like TH overlapped with lymphomas and autoimmunity in 
three female and four male and seven female and five male patients, respectively, of whom one 
male suffered from all three diseases. One female showed autoimmunity and lymphoma without 
LESA-like TH. 
4. Discussion 
Based on the largest cohort of patients to date, we report on two clinically and di-
agnostically important new features observed in LESA-like TH that distinguish it from 
”conventional” TFH: the association with lymphoma and mainly non-myasthenic auto-
immune diseases, and the near total absence of thymic cortical structures even in corti-
costeroid-naïve patients. 
These current new findings have the following implications for patient care: First, 
the classification of LESA-like TH as benign should be complemented by the fact that 
more than 10% of patients have a concomitant lymphoma at the time of surgery. There-
fore, the pathological workup of thymectomy specimens must not only exclude thymoma 
but also lymphoma. To pursue this workflow, it is important not to misconceive LE-
SA-like TH as unusually large but “innocent” TFH; recognition of a missing thymic cor-
tex as a hallmark of LESA-like TH aids in this differential. Second, postoperative staging 
procedures in case of LESA-like TH-associated lymphomas appear mandatory like in 
other lymphoma settings, although dissemination requiring chemotherapy was restricted 
to the one DLBCL in our cohort. Third, since the course of LESA-like TH-associated 
lymphomas after surgery and the impact of radical surgery on the risk of lymphoma re-
currence are unknown, long-term clinical follow-up is important, in order to learn 
whether adjuvant therapy may be beneficial after surgery. Fourth, radiologists and clini-
cians should be aware of LESA-like TH as a potential—albeit rare—differential diagnosis 
for mediastinal mass lesions in patients with autoimmune diseases. Fifth, clinical fol-
Figure 4. Venn diagram visualizing the overlaps between LESA-like TH, lymphomas and autoim une diseases. A synopsis
of both cohorts, i.e., LESA-like TH (Table 1) and lymphoma (Table 2), is shown with the overlaps between the diagnoses of
LESA-like TH (LESA), lymphoma (Lym.) and autoimmune disorders ( utoimm.) together wit the gender distribution
(M, male; F, female). Six female and 14 male patients showed LESA-like TH only, while one male and seven female patients
exclusively showed lymphoma. LESA-like TH overlapped with lymphomas and autoimmunity in three female and four
male and seven female and five male patients, respectively, of whom one male suffered from all three diseases. One female
showed autoimmunity and lymphoma without LESA-like TH.
4. Discussion
Based on the largest cohort of patients to date, we report on two clinically and diag-
nostically important new features observed in LESA-like TH that distinguish it from ”con-
ventional” TFH: the association with lymphoma and mainly non-myasthenic autoimmune
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diseases, and the near total absence of thymic cortical structures even in corticosteroid-
naïve patients.
These current new findings have the following implications for patient care: First,
the classification of LESA-like TH as benign should be complemented by the fact that more
than 10% of patients have a concomitant lymphoma at the time of surgery. Therefore,
the pathological workup of thymectomy specimens must not only exclude thymoma
but also lymphoma. To pursue this workflow, it is important not to misconceive LESA-
like TH as unusually large but “innocent” TFH; recognition of a missing thymic cortex
as a hallmark of LESA-like TH aids in this differential. Second, postoperative staging
procedures in case of LESA-like TH-associated lymphomas appear mandatory like in other
lymphoma settings, although dissemination requiring chemotherapy was restricted to the
one DLBCL in our cohort. Third, since the course of LESA-like TH-associated lymphomas
after surgery and the impact of radical surgery on the risk of lymphoma recurrence are
unknown, long-term clinical follow-up is important, in order to learn whether adjuvant
therapy may be beneficial after surgery. Fourth, radiologists and clinicians should be aware
of LESA-like TH as a potential—albeit rare—differential diagnosis for mediastinal mass
lesions in patients with autoimmune diseases. Fifth, clinical follow-up is also required to
determine whether LESA-like TH resection might ameliorate the associated autoimmune
disorders as thymectomy ameliorates EOMG [7]. In our cohort, this was not the case,
but drawing conclusions may not yet be justified due to low case numbers. Nevertheless,
we anticipate that the many contrasting features of LESA-like TH and TFH will make their
further clinical, immunological and molecular comparison a promising scientific endeavor
with the perspective to better understand the thymic function, the pathogenesis of MG and
non-myasthenic autoimmune diseases and the impact of peripheral tolerance failure on
the thymus.
Since the age of the lymphoma-free patients with LESA-like TH in the current series
averaged 52 years, while the average age of patients with thymic MALT lymphoma was
slightly higher (58 and 56 years, in our and other studies, respectively [8]), we hypothe-
size that LESA-like TH could be a precursor lesion in at least a subset of thymic MALT
lymphomas. This idea is supported by the close spatial relationship between LESA-like
TH and the lymphomas and the detection of remnants of LESA-like TH in two of 11
thymic MALT lymphomas in an independent cohort (Figure 3 and Figure S2). LESA-like
TH-associated MALT lymphomas were peculiar in several respects: First, they did not
show the preferred IgA-restriction that was observed in 13 out of 15 thymic MALT lym-
phomas reported from Japan and China [9]. Second, 11 of those 15 MALT lymphomas
were associated with autoimmune diseases, while in our cohorts, only one of four patients
with LESA-like TH-associated MALT lymphoma and one of 11 MALT-lymphomas showed
autoimmune phenomena (Figure 4). Third, Sjögren syndrome, which occurred in eight
of the 15 patients with thymic MALT lymphomas and is the leading disease underlying
myoepithelial sialadenitis-associated lymphomas [10], was encountered in only one patient
with LESA-like TH and in only one patient suffering from a MALT lymphoma without
LESA-like TH. Fourth, 12 of the 15 MALT lymphoma patients in Inagaki et al.’s cohort [9]
(including 10 of 11 MALT lymphoma patients with associated autoimmunity) were females,
while the bias in our series was less pronounced (Figure 4). Whether these discrepancies
reflect ethnic differences or the absence of underlying LESA-like TH in the cases from Japan
and China cannot be decided. Similarly, it is unclear whether the association between the
one DLBCL with LESA-like TH is fortuitous. Although no residual MALT lymphoma com-
ponent was present in this case, the possibility of a high-grade transformation of thymic
MALT lymphoma has been reported previously [8]. Primary salivary gland high-grade
B-cell lymphomas occurring with or without a preceding MALT lymphoma have also been
observed in Sjögren syndrome [11,12].
It is unclear why LESA-like TH (similarly to micronodular thymoma with lymphoid
stroma) apparently predisposes to MALT lymphoma development while TFH in MG
patients does not [13]. In micronodular thymoma with lymphoid stroma, the micromilieu
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differs substantially from the one in TFH and is therefore suspected to interfere with B-cell
homoeostasis [13]. A similar scenario could be operative in LESA-like TH, as suggested by
a key histological difference between TFH and LESA-like TH: while TFH is compatible with
thymopoiesis as indicated by well-developed, TdT(+) cortical areas, LESA-like TH lacks
cortical structures even in corticosteroid-naïve patients (Figure 2). This feature of LESA-like
TH mimics the cytokine-induced abrogation of the thymic cortex and thymopoiesis in
mouse models [14,15] and in humans during severe infections [16,17].
Another unresolved puzzle is the high prevalence of non-myasthenic autoimmune
diseases and the paucity of MG in patients with LESA-like TH, while the opposite is typical
of patients with either EOMG or thymoma. Whereas the frequencies of pure red cell
aplasia, scleroderma and Graves’ disease in LESA-like TH (present in one patient each,
approx. 3%) were comparable with previous reports on thymoma and EOMG patients [18],
the prevalence of systemic lupus erythematosus (SLE) (n=4, 11%) and rheumatoid arthritis
(RA) (n = 3, 8%) was remarkably high in the LESA-like TH cohort as contrasted with
levels of 1–3% in thymomas [18,19] and EOMG [20]. The true incidence of autoimmune
diseases might be even higher in our cohort because in older cases (listed at the top of the
chronologically arranged Table 1), the clinical data were partially incomplete with regard
to autoimmunity. Furthermore, the clinical symptoms of Sjögren syndrome, which is
characterized by LESA of the lacrimal and salivary glands and frequently associated with
RA and SLE, are often less apparent and may with only one case be underdiagnosed
in this cohort. The pathogenesis of non-myasthenic autoimmune diseases associated
with LESA-like TH is unknown, echoing the poor understanding of their pathogenesis in
patients with EOMG and thymomas [21–23]. Likewise, it is unclear why MG is so rare in
LESA-like TH. A different genetic background is a possible explanation, since only one
patient with anti-AChR positive MG was encountered, and the other two LESA-like TH
patients with MG-associated autoantibodies did not suffer from EOMG: One patient at
age 67 had non-thymomatous, anti-titin/anti-AChR autoantibody-positive late-onset MG
(LOMG), while the other patient (without overt MG symptoms) had anti-MuSK antibodies.
Apart from these two patients, LOMG and anti-MuSK-MG typically do not emerge in
the context of thymic pathology but have been thought to reflect a loss of peripheral
tolerance [24,25]. Unfortunately, lack of blood or fresh material in all of these consultation
cases precluded HLA-typing. Another mechanism that could underlie the rarity of MG in
LESA-like TH is the consistent, near complete absence of thymopoiesis in LESA-like TH;
this property is held responsible for the low incidence of MG in type A and metaplastic
thymomas and thymic carcinomas [26], while thymopoiesis in thymomas and rare non-
thymic tumors is strongly linked to MG development [23,27].
The main limitation of this study is the relatively small number of cases. Although
the number of analyzed LESA-TH cases is unprecedented, it is too low to deduce reliable
frequencies of lymphoproliferative and autoimmune diseases in these patients. The retro-
spective character of the analysis that is almost only based on consultation cases hampered
the retrieval of clinical information and follow-up data.
In view of these facts, prospective studies are needed to (1) assess the incidence
and full spectrum of autoimmune diseases and lymphomas in LESA-like TH patients;
(2) to learn whether thymectomy has an impact on the autoimmune symptoms of patients
with LESA-like TH and (3) to elucidate the clinical behavior of LESA-like TH-associated
lymphomas following thymectomy. Moreover, a thorough comparison of molecular and
genetic features (including genetic backgrounds) of LESA-like TH and ”conventional” TH
appears highly promising to decipher the aberrant immunoregulatory mechanisms that
underlie the high risk to develop mainly non-myasthenic autoimmunity and lymphomas
in the former as compared to mainly MG development and protection from lymphomas in
the latter.
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5. Conclusions
In summary, the above findings show that LESA-like TH is not just an “exaggerated”,
tumor-forming variant of TFH but, rather, a disease of its own standing with a remarkably
high incidence of associated autoimmune diseases and lymphomatous transformation.
These new findings argue for an in-depth workup of LESA-like TH resection specimens
and a meticulous clinical management of LESA-like TH patients. Moreover, radiologists
and clinicians should be aware of LESA-like TH as a differential diagnosis for mediastinal
mass lesions in patients with autoimmune diseases.
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